Clinical Trial Update: NeisVac-C Single Prime Study in Infants [Phase 3]

View source ↗

Summary

Pfizer's NeisVac-C single-prime Phase 3 trial in infants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Invasive Meningococcal Disease
• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• NeisVac-C (Meningococcal conjugate vaccine against Neisseria meningitidis group C)

Snippet

Sponsor: Pfizer | Conditions: Neisseria Meningitidis | Phase 3 | Status: COMPLETED